Understanding Cladribine Multiple Sclerosis Therapy and Long-Term Remission

Managing relapsing forms of central nervous system demyelination has changed dramatically with pulsed immune reconstitution therapies. Specifically, cladribine multiple sclerosis regimens offer patients a distinct approach that selectively depletes lymphocytes and allows subsequent immune system reconstitution. Clinicians typically administer this medication in two short courses spaced one year apart during the first two treatment years. Consequently, this schedule provides patients with prolonged periods free of regular dosing. Clinical trials previously demonstrated high efficacy in reducing annualized relapse rates and suppressing new inflammatory lesions. However, physicians in routine clinical practice often encounter questions regarding long-term disease stability after patients complete the standard two-year treatment course. Real-world evidence remains vital because patient populations in general clinics display greater heterogeneity than trial cohorts. Furthermore, neurologists must understand how long immune reset lasts before disease recurrence occurs. Therefore, evaluating real-world cohorts after treatment cessation addresses an essential knowledge gap in contemporary neuroimmunology. Recent findings from the multicenter CladStop cohort provide invaluable insights into the durability of clinical benefits and the necessity of re-treatment.

Methodology and Follow-Up of the Multicenter CladStop Cohort

To characterize post-treatment disease dynamics, investigators established the multicenter CladStop observational cohort study across multiple neurology departments. The researchers included 204 adult patients with relapsing multiple sclerosis who successfully completed the full two-year cladribine regimen. Importantly, every included patient maintained at least six months of clinical follow-up after completing their second treatment course. The investigators defined the baseline anchor point, termed CladStop, precisely twenty-four months after patients received their very first cladribine dose. Subsequently, researchers monitored participants over an extended mean follow-up period of 44.2 months. The study authors designated two co-primary endpoints to gauge therapeutic durability effectively. Specifically, they evaluated the time to loss of no evidence of disease activity, known widely as NEDA-3, and the post-treatment annualized relapse rate. In addition, the team implemented robust statistical techniques, including Kaplan-Meier survival curves, multivariable Cox proportional hazards models, and mixed-effects Poisson regression models. Consequently, these thorough methodologies enabled researchers to adjust for critical baseline confounders and calculate accurate risk estimates over extended observational windows.

Annualized Relapse Rates and Disability Progression Beyond Year Two

The clinical outcomes from the CladStop cohort demonstrated sustained disease suppression across a significant proportion of participants. During the extended post-treatment period, only forty-two patients experienced a clinical relapse, representing approximately 20.6% of the cohort. Furthermore, the overall annualized relapse rate reached an impressive 0.06 events per patient-year. Interestingly, longitudinal analysis revealed that relapse rates decreased significantly over time rather than accelerating after drug clearance. Mixed-effects Poisson regression indicated a rate ratio of 0.74 per year, proving statistically significant at p = 0.044. Moreover, confirmed disability progression remained uncommon among these patients. Investigators confirmed six-month disability worsening on the Expanded Disability Status Scale in only 7.4% of the entire cohort. Therefore, these findings strongly suggest that cladribine provides durable neuroprotection that persists long after the drug leaves circulating plasma. However, clinicians must remember that a minor subset of patients continues to experience recurrent clinical episodes. Hence, regular neurological physical evaluations remain indispensable during routine post-treatment consultations.

Evaluating NEDA-3 Loss and Radiological Reactivation Patterns

Although relapse rates remained exceptionally low, comprehensive disease activity assessments demonstrated progressive loss of clinical remission over time. Overall, eighty-one out of 204 patients, or 39.7%, lost their NEDA-3 status during extended follow-up. Kaplan-Meier survival analysis revealed that the cumulative NEDA-3 retention rate was 82.8% at twelve months post-treatment. Subsequently, this proportion declined to 69.6% at twenty-four months and reached 56.4% at forty-eight months. Detailed breakdown of individual NEDA-3 components demonstrated that subclinical inflammatory activity represented the primary driver of disease reactivation. Specifically, new or enlarging magnetic resonance imaging lesions occurred in 29.9% of all patients. In contrast, physical disability progression contributed minimally to the overall loss of disease freedom. Thus, subclinical radiological activity frequently heralded disease return before noticeable clinical symptoms emerged. Because asymptomatic inflammatory lesions can accumulate silently, neurologists should not rely solely on clinical symptom reports. Instead, regular surveillance neuroimaging provides crucial early warnings of immunologic reactivation, allowing proactive management decisions before functional disability accrues.

Predictors of Therapy Re-Initiation and Subsequent DMT Selection

Because disease activity returned in a notable subgroup, clinicians frequently initiated subsequent disease-modifying therapies during the post-CladStop observation period. Overall, 40.7% of patients transitioned to an alternative disease-modifying therapy after completing their initial treatment cycles. Multivariable Cox models demonstrated that experiencing clinical relapses during the two-year treatment course strongly predicted earlier re-initiation of therapy. Consequently, early breakthrough inflammatory activity identifies patients who require closer clinical surveillance. In addition, magnetic resonance imaging lesion accumulation prompted many clinicians to switch treatments before permanent neurological deficits developed. Importantly, these findings indicate that treatment-free remission does not last indefinitely for all patients. While some individuals maintain excellent biological control for several years, others require ongoing pharmacologic intervention. Therefore, neurologists should consider cladribine as an induction or pulsed therapy that may require subsequent sequential treatments. Clinicians must establish clear protocols for monitoring biomarkers, clinical status, and imaging features to guide timely therapeutic switches when disease breakthrough occurs.

Clinical Implications for Practice and Patient Monitoring Strategies

The real-world evidence from the CladStop cohort offers meaningful guidance for everyday neurological practice. First, healthcare providers can reassure appropriate patients that cladribine provides durable disease suppression with an exceptionally low annualized relapse rate. Furthermore, the low rate of confirmed disability progression underscores the strong neuroprotective potential of pulsed immune reconstitution. However, practitioners must communicate realistic expectations regarding the durability of treatment-free periods. Over forty percent of individuals eventually require another disease-modifying therapy, emphasizing that MS management remains a long-term journey. Moreover, because radiological breakthroughs occur far more frequently than overt clinical relapses, scheduled surveillance magnetic resonance imaging remains essential. Neurologists should schedule regular brain scans annually or biennially to catch silent inflammatory lesions early. In addition, when relapses occur during active treatment years, clinicians must maintain high vigilance and prepare for earlier therapeutic escalation. Thus, proactive surveillance combined with personalized sequencing strategies ensures that patients sustain optimal neurological function over their lifetime.

Frequently Asked Questions

What was the primary objective of the CladStop extended follow-up study?

The multicenter CladStop study evaluated long-term clinical durability, treatment re-initiation patterns, and safety in relapsing multiple sclerosis patients. Specifically, investigators analyzed outcomes after individuals completed the standard two-year oral cladribine regimen. The research tracked disease activity, radiological breakthroughs, and subsequent therapy requirements across an extended average follow-up period exceeding forty-four months.

How long does disease remission typically persist without further therapy?

The study revealed that disease control remained durable for several years in many patients. Specifically, NEDA-3 survival was 82.8% at twelve months, 69.6% at twenty-four months, and 56.4% at forty-eight months post-treatment. Nevertheless, inflammatory activity eventually returned in over forty percent of individuals, demonstrating that indefinite treatment-free remission is not universal.

Which factors predict the early need for subsequent disease-modifying therapy?

The occurrence of clinical relapses during the initial two-year treatment course strongly predicted earlier initiation of subsequent disease-modifying therapies. Furthermore, subclinical radiological breakthrough lesions served as a primary trigger for re-intervention. Consequently, clinicians must maintain close monitoring through regular neurological assessments and serial magnetic resonance imaging scans to detect early recurrence.

Disclaimer: This content is for informational and educational purposes only. It is not intended to provide medical advice, diagnosis, or treatment. Healthcare professionals should make decisions based on each patient’s clinical profile. The opinions and interpretations expressed belong solely to the original authors and do not necessarily represent those of the publisher or any referenced institutions. Refer to the latest local and national guidelines for clinical practice.

References

1. Schiavetti I et al. Long-Term Disease Control Following Completion of Cladribine Treatment in Multiple Sclerosis: Extended Follow-Up of the CladStop Cohort. Eur J Neurol. 2026 Nov. doi: 10.1111/ene.70763. PMID: 42963188.


2. Giovannoni G, Comi G, Cook S, et al. Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study. Mult Scler. 2023;29(6):712-721. doi:10.1177/13524585231161494.


3. Moser T, Sellner J, Ziemssen T. Real-world evidence for cladribine tablets in multiple sclerosis: further insights into efficacy and safety. Ther Adv Neurol Disord. 2022;15:17562864221092234. doi:10.1177/17562864221092234.